Il y a eu 50 transactions d'initiés récentes enregistrées pour Atrium Therapeutics, Inc. (RNA), dont 17 achats et 29 ventes. Le total des achats d'initiés s'élève à $16.86M et le total des ventes d'initiés à $8.27M.
Les initiés notables ayant une activité récente comprennent Gallagher Kathleen P., Flanagan W. Michael, Levin Arthur A. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — RNA
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2025-06-17 |
Gallagher Kathleen P. |
Chief Program Officer |
Vente Informative |
911 |
$30.24 |
$27.55K |
50,392 |
| 2025-06-11 |
Flanagan W. Michael |
Chief Scientific Officer |
Vente Informative |
20,000 |
$32.88 |
$657.69K |
80,195 |
| 2025-06-10 |
Levin Arthur A |
Director |
Attribution de RSU |
10,034 |
$33.62 |
$337.34K |
10,034 |
| 2025-06-10 |
Boess Carsten |
Director |
Attribution de RSU |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Kaye Edward M. Md |
Director |
Attribution de RSU |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Wilson Troy Edward |
Director |
Attribution de RSU |
10,034 |
$33.62 |
$337.34K |
10,034 |
| 2025-06-10 |
Henig Noreen |
Director |
Attribution de RSU |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Thompson Tamar |
Director |
Attribution de RSU |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Kim Jean Jinsun |
Director |
Attribution de RSU |
6,692 |
- |
- |
6,692 |
| 2025-06-10 |
Skerjanec Simona |
Director |
Attribution de RSU |
6,692 |
- |
- |
6,692 |
| 2025-06-02 |
Gallagher Kathleen P. |
Chief Program Officer |
Exercice d'Options (Vente) |
5,875 |
$16.65 |
$97.82K |
22,596 |
| 2025-05-01 |
Gallagher Kathleen P. |
Chief Program Officer |
Exercice d'Options (Vente) |
5,875 |
$16.65 |
$97.82K |
28,471 |
| 2025-04-01 |
Gallagher Kathleen P. |
Chief Program Officer |
Exercice d'Options (Vente) |
5,546 |
$14.70 |
$81.53K |
13,829 |
| 2025-03-20 |
Maclean Michael F |
Chief Financial Officer |
Vente Informative |
7,935 |
$31.06 |
$246.42K |
96,720 |
| 2025-03-20 |
Boyce Sarah |
President and CEO |
Vente Informative |
31,540 |
$31.06 |
$979.56K |
305,871 |
| 2025-03-20 |
Hughes Steven George |
Chief Medical Officer |
Vente Informative |
9,578 |
$31.06 |
$297.49K |
72,850 |
| 2025-03-20 |
Flanagan W. Michael |
Chief Scientific Officer |
Vente Informative |
11,780 |
$31.06 |
$365.87K |
80,195 |
| 2025-03-20 |
Mccarthy Teresa |
Chief Human Resources Officer |
Vente Informative |
7,778 |
$31.06 |
$241.58K |
97,130 |
| 2025-03-11 |
Flanagan W. Michael |
Chief Scientific Officer |
Vente Informative |
20,000 |
$30.13 |
$602.61K |
91,975 |
| 2025-03-03 |
Gallagher Kathleen P. |
Chief Program Officer |
Exercice d'Options (Vente) |
5,875 |
$14.70 |
$86.36K |
19,375 |
| 2025-02-03 |
Gallagher Kathleen P. |
Chief Program Officer |
Exercice d'Options (Vente) |
5,875 |
$16.65 |
$97.82K |
34,675 |
| 2025-01-22 |
Gallagher Kathleen P. |
Chief Program Officer |
Vente Informative |
5,629 |
$30.16 |
$169.78K |
50,554 |
| 2025-01-21 |
Levin Arthur A |
Director |
Vente Informative |
1,872 |
$28.60 |
$53.54K |
12,958 |
| 2025-01-21 |
Maclean Michael F |
Chief Financial Officer |
Vente Informative |
1,665 |
$28.59 |
$47.61K |
104,655 |
| 2025-01-21 |
Boyce Sarah |
President and CEO |
Vente Informative |
5,659 |
$28.59 |
$161.82K |
337,411 |
| 2025-01-21 |
Hughes Steven George |
Chief Medical Officer |
Vente Informative |
2,032 |
$28.59 |
$58.1K |
82,428 |
| 2025-01-21 |
Flanagan W. Michael |
Chief Scientific Officer |
Vente Informative |
1,812 |
$28.59 |
$51.81K |
91,975 |
| 2025-01-21 |
Mccarthy Teresa |
Chief Human Resources Officer |
Vente Informative |
1,221 |
$28.60 |
$34.92K |
104,908 |
| 2025-01-21 |
Gallagher Kathleen P. |
Chief Program Officer |
Vente Informative |
1,817 |
$28.59 |
$51.95K |
56,183 |
| 2025-01-06 |
Maclean Michael F |
Chief Financial Officer |
Attribution de RSU |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Moriarty John B |
Chief Legal Officer |
Attribution de RSU |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Boyce Sarah |
President and CEO |
Attribution de RSU |
165,000 |
$31.42 |
$5.18M |
165,000 |
| 2025-01-06 |
Mosbrooker Eric |
Chief Commercial Officer |
Inconnu |
315,000 |
$9.05 |
$2.85M |
- |
| 2025-01-06 |
Mosbrooker Eric |
Chief Commercial Officer |
Attribution de RSU |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Hughes Steven George |
Chief Medical Officer |
Inconnu |
84,625 |
$15.96 |
$1.35M |
- |
| 2025-01-06 |
Hughes Steven George |
Chief Medical Officer |
Attribution de RSU |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Flanagan W. Michael |
Chief Scientific Officer |
Attribution de RSU |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Mccarthy Teresa |
Chief Human Resources Officer |
Attribution de RSU |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Gallagher Kathleen P. |
Chief Program Officer |
Inconnu |
16,000 |
$44.00 |
$704K |
- |
| 2025-01-06 |
Gallagher Kathleen P. |
Chief Program Officer |
Attribution de RSU |
50,000 |
$31.42 |
$1.57M |
50,000 |
| 2025-01-06 |
Calderaro Charles Iii |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-01-06 |
Calderaro Charles Iii |
Chief Technical Officer |
Attribution de RSU |
40,000 |
- |
- |
40,000 |
| 2024-12-18 |
Maclean Michael F |
Chief Financial Officer |
Vente Informative |
11,151 |
$32.66 |
$364.19K |
82,942 |
| 2024-12-18 |
Boyce Sarah |
President and CEO |
Vente Informative |
31,855 |
$32.66 |
$1.04M |
265,308 |
| 2024-12-18 |
Flanagan W. Michael |
Csto |
Vente Informative |
12,742 |
$32.66 |
$416.15K |
72,647 |
| 2024-12-18 |
Mccarthy Teresa |
Chief Human Resources Officer |
Vente Informative |
11,151 |
$32.66 |
$364.19K |
82,867 |
| 2024-12-16 |
Mccarthy Teresa |
Chief Human Resources Officer |
Exercice d'Options (Vente) |
25,000 |
$14.22 |
$355.5K |
57,500 |
| 2024-12-11 |
Flanagan W. Michael |
Csto |
Vente Informative |
24,000 |
$35.77 |
$858.4K |
85,389 |
| 2024-11-19 |
Levin Arthur A |
Director |
Exercice d'Options (Vente) |
3,323 |
$1.24 |
$4.12K |
- |
| 2024-11-18 |
Mccarthy Teresa |
Chief Human Resources Officer |
Exercice d'Options (Vente) |
25,000 |
$14.22 |
$355.5K |
82,500 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
